Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via PyroptosisDan A. Erkes, Andrew E. Aplin|Cancer Discovery|2019Cited by 482
Akt3-Mediated Resistance to Apoptosis in B-RAF–Targeted Melanoma CellsYongping Shao, Andrew E. Aplin|Cancer Research|2010Cited by 194
Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanomaClaudia Capparelli, Andrew E. Aplin|Nature Communications|2022Cited by 98
<i>In Vivo</i> E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance MechanismsJessica L.F. Teh, Andrew E. Aplin|Cancer Discovery|2018Cited by 77
Fibroblast-derived Neuregulin 1 Promotes Compensatory ErbB3 Receptor Signaling in Mutant BRAF MelanomaClaudia Capparelli, Andrew E. Aplin|Journal of Biological Chemistry|2015Cited by 69